Suppr超能文献

支气管哮喘与慢性支气管炎患者痰液嗜酸性粒细胞阳离子蛋白水平的比较。

Comparison of sputum-ECP levels in bronchial asthma and chronic bronchitis.

作者信息

Virchow J C, Kroegel C, Hage U, Kortsik C, Matthys H, Werner P

机构信息

Department of Pneumology, University Medical Clinic, Freiburg, Germany.

出版信息

Allergy. 1993;48(17 Suppl):112-8; discussion 143-5. doi: 10.1111/j.1398-9995.1993.tb04712.x.

Abstract

Eosinophil cationic protein (ECP) is a cationic protein secreted by eosinophils with toxic properties for the respiratory epithelium. Sputum-ECP levels have been shown to correlate inversely with airflow obstruction in asthma. In the present study we investigated whether ECP concentrations are different between asthmatic patients and patients with chronic bronchitis. Sputum-ECP concentrations from seven patients with bronchial asthma and seven patients with chronic bronchitis matched for FEV1 were compared (FEV1 Asthma: 66.1 +/- 29.0% of predicted; FEV1 Chronic Bronchitis: 65.2 +/- 33.3% of predicted; p = n.s.). Furthermore, sputum-ECP levels in 4 asthmatic patients with severe airflow obstruction and in 1 patient with chronic bronchitis were measured before and after initiation of a 7-day oral therapy with methylprednisolone 20 mg BID. Changes in sputum-ECP values were compared with changes in FEV1 in these 5 patients. Sputum-ECP levels and pulmonary function were measured as previously described (Am Rev Respir Dis 1992: 145: 604). Sputum-ECP levels from asthmatics were significantly elevated compared with patients with chronic bronchitis: asthma: 893.4 +/- 346.2 micrograms/l per g sputum; chronic bronchitis: 30.0 +/- 8.5 micrograms/l per g sputum (p = 0.002). The degree of airway obstruction correlated with the sputum-ECP levels in asthmatic (r = 0.76, p = 0.05), but not in the patients with chronic bronchitis (r = 0.24, p = n.s.).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

嗜酸性粒细胞阳离子蛋白(ECP)是一种由嗜酸性粒细胞分泌的阳离子蛋白,对呼吸道上皮具有毒性。已表明痰中ECP水平与哮喘患者的气流阻塞呈负相关。在本研究中,我们调查了哮喘患者与慢性支气管炎患者的ECP浓度是否存在差异。比较了7例支气管哮喘患者和7例慢性支气管炎患者的痰ECP浓度,这些患者的第一秒用力呼气容积(FEV1)相匹配(哮喘患者的FEV1:预测值的66.1±29.0%;慢性支气管炎患者的FEV1:预测值的65.2±33.3%;p=无显著差异)。此外,在4例严重气流阻塞的哮喘患者和1例慢性支气管炎患者中,在开始为期7天的每日两次口服20mg甲基泼尼松龙治疗之前和之后测量了痰ECP水平。比较了这5例患者痰ECP值的变化与FEV1的变化。痰ECP水平和肺功能的测量方法如前所述(《美国呼吸与危重症医学杂志》1992年;145:604)。与慢性支气管炎患者相比,哮喘患者的痰ECP水平显著升高:哮喘患者:每克痰893.4±346.2微克/升;慢性支气管炎患者:每克痰30.0±8.5微克/升(p=0.002)。哮喘患者的气道阻塞程度与痰ECP水平相关(r=0.76,p=0.05),但慢性支气管炎患者则无此相关性(r=0.24,p=无显著差异)。(摘要截选至250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验